Ocugen

Thank you Chardan and Daniil Gataulin, Ph.D. for once again including Ocugen in this informative series. #ModifierGeneTherapy #GA

This week, Dr. Shankar Musunuri, Chairman, CEO & Co-founder of Ocugen sat down with Dr. Swayampakula Ramakanth, Managing Director, Equity Research at H.C. Wainwright & Co., LLC for a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference. During the session, Dr. Musunuri provided insights into recent milestones for the Phase 3 OCU400 liMeliGhT clinical trial and anticipated milestones for the OCU410 ArMaDa clinical trial, now in Phase 2. It was great to both make introductions and continue the conversation with investors at this important conference. #HCWainwrightGlobal

Dr. Shankar Musunuri will participate in the panel: "Persistent Challenges: Right-Sizing Regulations and Setting Standards Beyond the Biomedical Sphere." The primary goal of this workshop series is to identify short-, medium-, and long-term opportunities for U.S.- India biotechnology cooperation consistent with the initiative on Critical and Emerging Technology (iCET) and beyond. #collaboration #access 

Thank you, Investing News Network, for recognizing Ocugen as a longevity and anti-aging stock to watch: https://lnkd.in/e9NbA_XV #genetherapy #celltherapy #courageousinnovation

Ocugen’s CSO, Head of Research & Development, Dr. Arun Upadhyay, will be among the featured speakers at the 5th Annual Gene Therapy for Ophthalmic Disorders Summit in Boston, Mass. from September 10-12,  2024. Dr. Upadhyay will present “Advancements in Gene Therapy for Ophthalmic Disorders: Ocugen’s Clinical Program Updates” at 11:30 a.m. on Thursday, September 12. 

Ocugen’s Chairman of the Board, CEO, & Co-Founder, Shankar Musunuri, will participate in a fireside chat on September 9, 2024, at the H.C. Wainwright Global Investment Conference. During the conference, members of Ocugen’s executive team will conduct one-on-one meetings to showcase the Company’s business and clinical development strategy across its unique modifier gene therapy platform. Read the full press release for more details: https://bit.ly/4e95hPb

Today we celebrate American workers' social and economic achievements. A special thank you to our talented Ocugen team members who work hard every day in service of patients. #LaborDay

Thank you Bryan Manning and Clinical Enrollment for raising awareness for our OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa and Ocugen's gene-agnostic approach to treating blindness diseases. #ClinicalTrials #ModifierGeneTherapy https://lnkd.in/eBzgTZUx

Ocugen CMO, Dr. Huma Qamar’s, most recent article “A Vision for Inclusion: Designing Trials That Benefit Visually Impaired Patients” has been published in Clinical Leader. She provides her perspective on the need to overcome hurdles in developing clinical trials for small patient populations with the unique needs of visually impaired patients in mind. Read the full article here: https://bit.ly/4cS6clX

Today, Ocugen announced the completion of dosing subjects in the high dose cohort of Phase 1/2 GARDian clinical trial of OCU410ST, a modifier gene therapy candidate being developed for Stargardt disease. Stargardt disease affects approximately 100,000 people in the United States and Europe. Read the full press release here: https://bit.ly/3Xn689F #genetherapy #Stargardt